New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease

Brassington, K, Selemidis, S, Bozinovski, S and Vlahos, R 2019, 'New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease', Clinical Science, vol. 133, no. 7, pp. 885-904.

Document type: Journal Article
Collection: Journal Articles

Title New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease
Author(s) Brassington, K
Selemidis, S
Bozinovski, S
Vlahos, R
Year 2019
Journal name Clinical Science
Volume number 133
Issue number 7
Start page 885
End page 904
Total pages 20
Publisher Portland Press
Abstract Chronic obstructive pulmonary disease (COPD) is a disease characterised by persistent airflow limitation that is not fully reversible and is currently the fourth leading cause of death globally. It is now well established that cardiovascular-related comorbidities contribute to morbidity and mortality in COPD, with approximately 50% of deaths in COPD patients attributed to a cardiovascular event (e.g. myocardial infarction). Cardiovascular disease (CVD) and COPD share various risk factors including hypertension, sedentarism, smoking and poor diet but the underlying mechanisms have not been fully established. However, there is emerging and compelling experimental and clinical evidence to show that increased oxidative stress causes pulmonary inflammation and that the spill over of pro-inflammatory mediators from the lungs into the systemic circulation drives a persistent systemic inflammatory response that alters blood vessel structure, through vascular remodelling and arterial stiffness resulting in atherosclerosis. In addition, regulation of endothelial-derived vasoactive substances (e.g. nitric oxide (NO)), which control blood vessel tone are altered by oxidative damage of vascular endothelial cells, thus promoting vascular dysfunction, a key driver of CVD. In this review, the detrimental role of oxidative stress in COPD and comorbid CVD are discussed and we propose that targeting oxidant-dependent mechanisms represents a novel strategy in the treatment of COPD-associated CVD.
Subject Respiratory Diseases
Basic Pharmacology
Keyword(s) Mean Platelet Volume
Induced Lung Inflammation
Focal Cerebral-Ischemia
Short-Term Response
Oxidative Stress
Nadph Oxidases
Glutathione Peroxidase-1
DOI - identifier 10.1042/CS20180316
Copyright notice © 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND).
ISSN 0143-5221
NHMRC Grant ID 1120522
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Altmetric details:
Access Statistics: 35 Abstract Views  -  Detailed Statistics
Created: Thu, 23 May 2019, 08:44:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us